This work is licensed under a Creative Commons Attribution 4.0 International License.
API5 derived peptides
General Information
DRACP ID DRACP01837
Peptide Name API5 derived peptides
Sequence LEDVTGEEF
Sequence Length 9
UniProt ID Not available
PubChem CID Not available
Origin API5 derived peptides
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| HeLa | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | As shown in Figure 26, anticancer effects of API5-derived peptides (API5) or FGF2-derived peptides (FGF2) on cervical cancer, liver cancer, kidney cancer, or pancreatic cancer cell lines were confirme | MTT assay | 48 h | Patent |
| Ca Ski | Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri | Carcinoma | As shown in Figure 26, anticancer effects of API5-derived peptides (API5) or FGF2-derived peptides (FGF2) on cervical cancer, liver cancer, kidney cancer, or pancreatic cancer cell lines were confirme | MTT assay | 48 h | Patent |
| Hep 3B2.1-7 | Childhood hepatocellular carcinoma; Pediatric hepatocellular carcinoma | Carcinoma | As shown in Figure 26, anticancer effects of API5-derived peptides (API5) or FGF2-derived peptides (FGF2) on cervical cancer, liver cancer, kidney cancer, or pancreatic cancer cell lines were confirme | MTT assay | 48 h | Patent |
| PLC/PRF/5 | Adult hepatocellular carcinoma; | Carcinoma | As shown in Figure 26, anticancer effects of API5-derived peptides (API5) or FGF2-derived peptides (FGF2) on cervical cancer, liver cancer, kidney cancer, or pancreatic cancer cell lines were confirme | MTT assay | 48 h | Patent |
| ACHN | Papillary renal cell carcinoma | Carcinoma | As shown in Figure 26, anticancer effects of API5-derived peptides (API5) or FGF2-derived peptides (FGF2) on cervical cancer, liver cancer, kidney cancer, or pancreatic cancer cell lines were confirme | MTT assay | 48 h | Patent |
| Caki-2 | Papillary renal cell carcinoma | Carcinoma | As shown in Figure 26, anticancer effects of API5-derived peptides (API5) or FGF2-derived peptides (FGF2) on cervical cancer, liver cancer, kidney cancer, or pancreatic cancer cell lines were confirme | MTT assay | 48 h | Patent |
| Mia PaCa-2 | Pancreatic ductal adenocarcinoma | Carcinoma | As shown in Figure 26, anticancer effects of API5-derived peptides (API5) or FGF2-derived peptides (FGF2) on cervical cancer, liver cancer, kidney cancer, or pancreatic cancer cell lines were confirme | MTT assay | 48 h | Patent |
| AsPC-1 | Pancreatic ductal adenocarcinoma | Carcinoma | As shown in Figure 26, anticancer effects of API5-derived peptides (API5) or FGF2-derived peptides (FGF2) on cervical cancer, liver cancer, kidney cancer, or pancreatic cancer cell lines were confirme | MTT assay | 48 h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C45H67N9O19
Absent amino acids ACHIKMNPQRSWY
Common amino acids E
Mass 118095
Pl 3.33
Basic residues 0
Acidic residues 4
Hydrophobic residues 3
Net charge -4
Boman Index -1884
Hydrophobicity -47.78
Aliphatic Index 75.56
Half Life
Mammalian: 1.3 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 2
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID WO2021/025352A1
Patent Title Anticancer Virus Expressing Fgf2- or Api5-Derived Peptide, and Use Thereof
Other Iinformation Patent Application; Family: 3s / 3ex; Family Jurisdictions: WO, KR; Legal Status: Pending; Application No: 2020009856; Filed: Jul 27, 2020; Published: Feb 11, 2021; Earliest Priority: Aug 8, 2019
Other Published ID KR102241134B1 KR20210017560A
This work is licensed under a Creative Commons Attribution 4.0 International License.